Literature DB >> 31556219

Whole-exome sequencing reveals the subclonal expression of NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.

Yoshinori Tsurusaki1,2, Jun-Ichi Nagai3, Sachio Fujita4, Masanaka Sugiyama4, Wataru Nakamura4, Akiko Hayashi4, Naoyuki Miyagawa4, Dai Keino4, Tomoko Yokosuka4, Fuminori Iwasaki4, Satoshi Hamanoue4, Masae Shiomi4, Shoko Goto4, Kenji Kurosawa5, Hiroaki Goto4.   

Abstract

Entities:  

Year:  2019        PMID： 31556219     DOI： 10.1002/pbc.28019

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  2 in total

1.  Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.

Authors:  Egle Stukaite-Ruibiene; Rimvydas Norvilas; Vaidas Dirse; Sigita Stankeviciene; Goda Elizabeta Vaitkeviciene
Journal:  Pathol Oncol Res       Date:  2022-09-12       Impact factor: 2.874

2.  Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing.

Authors:  Huan-Ping Wang; Jun-Jun He; Qiao-Yun Zhu; Lin Wang; Jian-Hu Li; Jian-Song Huang; Wan-Zhuo Xie; Hong-Hu Zhu; Jie Jin
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.